Citrate Versus Heparin in Continuous Renal Replacement Therapy :

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

January 15, 2021

Study Completion Date

March 31, 2021

Conditions
Acute Kidney InjuryCitrateCytokinesHemodynamic Responses
Interventions
PROCEDURE

Regional citrate anticoagulation

"The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6)."

Trial Locations (1)

10300

Faculty of Medicine ,Vajira hospital,Navamindradhiraj University, Bangkok

All Listed Sponsors
collaborator

King Chulalongkorn Memorial Hospital

OTHER

collaborator

Chiang Mai University

OTHER

collaborator

Department of Medicine, Somdech Phra Pinklao Hospital, Bangkok, Thailand.

UNKNOWN

lead

Bangkok Metropolitan Administration Medical College and Vajira Hospital

OTHER_GOV

NCT04865510 - Citrate Versus Heparin in Continuous Renal Replacement Therapy : | Biotech Hunter | Biotech Hunter